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Abstract 
Background: Although discovery research has identified the importance of dozens of pro- and anti-inflammatory 
immune mediators in the pathogenesis, maintenance, exacerbation and resolution of inflammatory diseases, most 
human cohort studies have incorporated few or no immunological intermediate phenotypes in their analyses. 
Significant hindrances have been (1) the limited panel of biomarkers known to be readily detected in healthy human 
populations and (2) the stability, hence utility, of such biomarkers to repeated analysis.
Methods: The frequency and stability of 14 plasma biomarkers linked to in vivo immune regulation of allergic and 
autoimmune inflammatory disorders was determined in 140 healthy pediatric and adult participants. The impact of 
initial and multiple subsequent freeze/thaw cycles on pro-inflammatory (CCL2, CXCL10, IL-18, TNFα, IL-6), anti-inflam-
matory (IL-10, sTNF-RII, IL-1Ra), acute phase proteins (CRP, PTX3) and other biomarkers (sST2, IL-1RAcP) was subse-
quently quantified.
Results: Multiple biomarkers capable of providing an innate immune signature of inflammation were readily 
detected directly ex vivo in healthy individuals. These biomarker levels were unaffected when comparing paired data 
sets from freshly obtained, never frozen plasma or serum and matched aliquots despite extensive freeze/thaw cycles. 
Neither age nor sex affected stability. Similarly, no quantitative differences were found following repetitive analysis of 
inflammatory biomarkers in culture samples obtained following in vitro stimulation with TLR and RLR ligands.
Conclusions: A broad panel of in vivo and ex vivo cytokine, chemokine and acute phase protein biomarkers that 
have been linked to human chronic inflammatory disorders are readily detected in vivo and remain stable for analysis 
despite multiple freeze thaw cycles. These data provide the foundation and confidence for large scale analyses of 
panels of inflammatory biomarkers to provide better understanding of immunological mechanisms underlying health 
versus disease.
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Background
Cohorts that range from hundreds to tens of thousands 
of individuals offer a powerful tool to validate, integrate 
and extend multidisciplinary findings obtained in basic 
biomedical discovery research. Currently, many human 
cohorts focus on identifying correlates of environmental 
variables (i.e. endotoxin exposure, birth order) with clini-
cal outcomes. With few exceptions [1–3], only a small 
proportion of such publications provide detailed exami-
nation of the intermediate phenotype of in vivo cytokine 
responses. For example, for allergic diseases, the most 
common chronic immune disorder in humans, PubMed 
identifies over 2000 publications for “birth cohort and 
allergy,” but <10% (155 citations) incorporate “cytokine 
or IL*,” and of these, only a subset examine inflammatory 
cytokines. Recent meta-analyses identify the knowledge 
gap resulting from this omission [4–8]. Given that most 
allergic and autoimmune disorders are driven by dysfunc-
tional immune regulation, this identifies an important, 
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of endotypes and mechanisms [9–12] underlying inflam-
matory diseases. The importance of doing so is increas-
ingly clear [13–22].
A major logistical challenge that impedes more wide-
spread adoption of such analyses is continuing uncer-
tainty about the stability of immune biomarkers in 
plasma, serum or tissue culture samples to repeated 
analysis. Repetitive freezing and thawing (F/T) cycles 
can induce protein instability and aggregation [23, 24]. 
Among immune biomarkers in complex biological fluids 
(i.e. plasma, culture supernatants), some studies indicate 
extreme sensitivity, while others report that minimal var-
iance results from the limited number of F/T cycles that 
are typically required. This controversy may arise from 
the limited number of cytokine biomarkers that have 
been examined to date, the small sample sizes often uti-
lized (i.e. frequently < 10 individuals), the fact that sev-
eral biomarkers examined are typically undetectable or 
at the limits of assay sensitivity in much of the healthy 
population examined (i.e. IL-6), hence substitution of 
spiked recombinant commercial proteins occurs as a sur-
rogate for in vivo biomarkers. To an even greater extent 
than discovery based research projects which examine 
20–40 individuals, cohorts face extensive logistical diffi-
culties that prohibit analyses without repeated cycles of 
F/T [25–27].
Here we test the hypothesis that exposure of immune 
pro- and anti-inflammatory biomarkers to at least five 
repeated F/T cycles introduces acceptable (i.e. mini-
mal and predictable) variation. Using a panel of 14 pro-
inflammatory (CCL2, CXCL10, IL-18, TNFα, IL-6), 
anti-inflammatory (IL-10, sTNF-RII, IL-1Ra), acute phase 
proteins (CRP, PTX3) and other biomarkers (sST2, IL-
1RAcP) of inflammatory disorders previously linked to 
asthma, other atopic disorders [28–31] and a wide range 
of other chronic inflammatory conditions in humans, 
we quantify the sensitivity to initial freezing as well as 
to repeated F/T cycles that are inevitable if large studies 
incorporate analyses of immunological intermediate phe-
notypes. The findings demonstrate that a broad panel of 
pro-inflammatory, anti-inflammatory, acute phase pro-
teins and other biomarkers of inflammatory diseases are 
readily amenable to analysis and should be more widely 
incorporated in large human cohort studies.
Methods
Participants
The Canadian Healthy Infant Longitudinal Development 
(CHILD) Study is a prospective longitudinal birth cohort 
of >3500 neonates [32]. In this report, following approval 
by the University of Manitoba Health Research Ethics 
Board, and written informed consent from each partici-
pant or their parent/guardian, non-fasting venous blood 
was obtained at the Winnipeg site to yield plasma and 
serum samples from 140 randomly selected participants 
(children and their parents).
Sample preparation
Peripheral blood was collected by venipuncture and used 
for plasma, serum and isolation of PBMC [33]. Briefly, 
samples were kept at room temperature during trans-
port and prior to processing. Plasma was collected from 
10-mL heparin Vacutainer tubes (BD, Mississauga, Can-
ada) by centrifugation (500g, 10  min). Serum was col-
lected from 6-mL silica-coated Vacutainer tubes (BD) 
by centrifugation (1000g, 10 min). Replicate plasma and 
serum sample aliquots (300 μL each) were prepared from 
each individual and then used within 24 h without freez-
ing and were frozen at −80 °C for one or five F/T cycles 
before analysis. All analyses were performed comparing 
paired samples from the same individuals. Because the 
goal was to determine the impact of repeated changes 
of state (i.e. freeze/thawing) on plasma and superna-
tant samples, rather than how many months or years a 
sample could be stored and retain its integrity, all sam-
ples that underwent freeze thaw cycles were carried out 
within 24 h when comparing never frozen plasma or cul-
ture supernatant with samples subjected to one or five 
F/T cycles. Paired analyses of one versus five F/T cycles 
were carried out with storage at −80 °C for a few days to 
a month in total. Samples were handled using standard 
laboratory conditions: thawed rapidly at 37 °C then kept 
on ice until analyzed.
PBMC isolation and cell culture
PBMC were prepared using Ficoll (GE Healthcare, Mis-
sissauga, Canada) and cultured (triplicates, 350,000 cells/
round bottom well in 200 μL, 24 h) in medium alone or 
with stimuli. Medium consisted of RPMI-1640 (Thermo 
Fisher Scientific, Mississauga, Canada) supplemented 
with 10% fetal bovine serum (GE Healthcare, Missis-
sauga, Canada), 1% l-glutamine (VWR International, 
Mississauga, Canada), 1% Antibiotic–Antimycotic 
(Thermo Fisher Scientific), and 0.1% 2-mercaptoethanol 
(Thermo Fisher Scientific). Innate stimuli used included 
TLR4 ligand LPS (0.4  ng/mL, InvivoGen, San Diego, 
CA) or RLR ligand Poly(I:C)/Lyovec (250  ng/mL, Invi-
voGen). All PBMC samples were cultured the day they 
were drawn. Supernatants were aliquoted and examined 
in parallel without ever freezing and after five F/T cycles 
at −80 and 37 °C.
Immunological assays
All analyses were carried out in duplicate with paired 
samples after 0–5 F/T cycles. 5% of sample pairs or 
triplets were repeated on a separate day. Meso Scale 
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Discovery (MSD, Rockville, Maryland) singleplex assays 
were used to analyze plasma, serum and culture super-
natants for CCL2, CRP, CXCL8, IL-6, IL-10, IL-18, IL-
1Ra, sTNF-RII and TNFα according to manufacturer`s 
instructions. MSD V-Plex assays were used to analyze 
plasma and supernatant levels of CXCL10. ELISA (alka-
line phosphatase-biotin coupled developing reagent with 
PNPP for development) was used to analyze plasma and 
serum levels of IL-1RAcP, PTX3, and sST2 (R&D Sys-
tems, Minneapolis, Minnesota) using ultrasensitive pro-
tocols as previously described [34]. ELISAs incorporated 
four serial dilutions of each sample (i.e. 1/2, 1/4, 1/8 and 
1/16) that were assessed against eight serial dilutions of 
fresh aliquots of a constant recombinant lab standard 
stored at −80  °C in individual 400  μL aliquots (Cedar-
lane, Burlington, Canada; PeproTech, Quebec, Canada; 
R&D Systems). In most experiments, median coefficients 
of intra-assay variation between assays were below 5% for 
MSD assays and 10–15% for ELISA. Inter-assay variation 
was typically <10–20%.
Statistics
Data were analyzed using GraphPad Prism (La Jolla, 
California). Each point represents a single sample from 
an individual aliquot that has undergone the indicated 
number of F/T cycles. Mann–Whitney or Wilcoxon 
Matched Pairs/Signed Rank tests were used for unpaired 
and paired data sets respectively. While the multiple 
comparisons used in this study would normally require 
use of Bonferroni corrections, to obtain maximum sen-
sitivity for detection of possible differences, significance 
was assessed at the lower threshold of a 95% confidence 
level (two-tailed p < 0.05).
Results
Detection and stability of pro‑ and anti‑inflammatory 
plasma biomarkers
Freshly obtained plasma (or sera, see below) from a study 
population of 140 individuals of whom 30 were pediatric 
were examined. Adults were 20–44 years of age (median 
32  year), while the pediatric population was aged 3 
(median 3.2  year). Due to the number of biomarkers 
examined, and logistical constraints on how many inde-
pendent assays could be performed simultaneously with 
never frozen samples, slightly different numbers of indi-
viduals were examined for each biomarker.
Figure  1a demonstrates that pro-inflammatory 
cytokines CCL2, CXCL10 and IL-18 are expressed at 
readily detectable levels in  vivo in all of the individu-
als examined and can serve as readily detectable plasma 
Fig. 1 Initial freezing, and up to five total freeze/thaw cycles, does not alter the levels of pro-inflammatory cytokines and chemokines in plasma. 
Each symbol represents an independent sample from a separate individual. Medians and p values from Wilcoxon matched pairs analyses are shown
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biomarkers in healthy human populations. When com-
paring fresh plasma with that from the same individuals 
after zero, one, or five F/T cycles (see “Methods” section), 
there was no detectable impact on the concentrations 
measured. Similarly, CXCL8, TNFα and IL-6 values in 
never frozen plasma versus 5 × F/T samples were indis-
tinguishable (p  >  0.05) in paired longitudinal analyses 
(Fig. 1b).
Endogenous controls of inflammation, such as anti-
inflammatory cytokines and immune response modi-
fiers, are pivotal yet are typically underrepresented in 
human studies of inflammation. Figure  2 reveals three 
points. Unlike pro-inflammatory biomarkers such as 
IL-6 and TNFα, where many healthy individuals exhibit 
extremely low levels, IL-10, sTNF-RII and IL-1Ra are 
readily detected in plasma of most individuals, hence can 
be readily measured in cohort studies. Secondly, an initial 
F/T cycle, virtually inevitable in practice, does not alter 
the results obtained upon analysis. These data are also 
presented in before/after plots (Additional file  1: Figure 
S1) to facilitate intra-individual comparisons. Finally, 
particularly important for studies where hundreds or 
thousands of samples require assessment, up to five F/T 
cycles had minimal impact on the levels measured.
A single exception was found among the 14 biomarkers 
examined. sTNF-RII differed when comparing 1× ver-
sus 5× F/T cycles (medians 1516 vs. 1470 pg/mL, a 3% 
increase, p = 0.002). We note that comparison of never 
frozen plasma and 5× F/T was not significant (medians 
1470 vs. 1516 pg/mL, p = 0.14). For context, the 3% dif-
ference seen comparing one and five F/T cycles contrasts 
with the 770% range (560–4365  pg/mL) in the popula-
tion. Thus, while the 1× versus 5× F/T is statistically 
significant (if it had not been corrected for multiple com-
parisons, as would normally be performed), the biologi-
cal relevance of a median 3% error in analysis elicited by 
freezing and thawing is minor in comparison to a 7.7 fold 
range in the population.
Stability of systemic inflammatory biomarkers: CRP, PTX3, 
IL‑1RAcP and sST2
We next examined a panel of widely used and emerg-
ing biomarkers of acute and chronic inflammation in 
humans (Fig.  3). These included CRP, historically the 
Fig. 2 Plasma anti-inflammatory biomarkers are stable despite repeated freeze/thaw cycles
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most commonly examined acute phase protein bio-
marker in humans; pentraxin 3 (PTX3), a systemic acute 
phase protein expressed in  vivo more rapidly than CRP 
and prominent in chronic inflammation; soluble IL-1R 
Accessory protein (IL-1RAcP), a widely expressed pro-
tein integral to pro-inflammatory signaling and linked 
to asthma, autoimmunity and other inflammatory con-
ditions; and sST2, an increasingly used predictive bio-
marker of inflammatory disorders and increased risk of 
mortality in cardiovascular disease. All were found to be 
ubiquitously expressed in plasma of healthy individuals. 
Each of these biomarkers was also stable when compar-
ing paired data sets from freshly obtained, never frozen 
plasma and matched aliquots after five F/T cycles.
Serum versus plasma stability to repeated F/T handling
The utility of plasma versus serum in biomarker quanti-
fication has been extensively studied. Here we focus on 
F/T stability of serum, examining a much broader range 
of immune analytes than previously reported. When 
serum was obtained from an individual and subjected 
to zero versus five repeat F/T cycles, the values obtained 
were stable. This conclusion applied to pro-  and anti-
inflammatory  cytokines (Fig.  4a) as well as acute phase 
proteins and other biomarkers (Fig. 4b). Importantly, and 
as previously established, levels for a given individual in 
serum versus plasma are frequently independent and are 
not necessarily interchangeable. Thus, paired analyses 
of serum and plasma from the same donors frequently 
yielded different values for some biomarkers whereas lev-
els of other biomarkers were indistinguishable in serum 
and plasma.
Impact of donor age or sex on F/T stability
Conclusions from experimental or clinical findings are 
sometimes extended from one age group or sex to another 
in the absence of clear supporting evidence. To avoid 
this, we stratified the study population by age, comparing 
samples within young children independently from those 
of adults (median age 3 vs. 32). Figure  5 demonstrates 
that F/T stability for the two pro-inflammatory (CCL2, 
IL-18; Fig.  5a) and two anti-inflammatory (IL-10, sTNF-
RII; Fig. 5b) molecules shown applies equally to pediatric 
populations. Similarly, male versus female donors did not 
Fig. 3 Stability of acute phase proteins and related plasma inflammatory biomarkers to at least five freeze/thaw cycles
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exhibit sex-attributable differences in stability of these 
biomarkers. CRP, PTX3, IL-1RAcP (encoded by IL1RAP) 
and sST2 (encoded by IL1RL1) were also stable within age 
and sex stratifications when comparing never frozen sam-
ples with those of five F/T cycles.
Stability of PRR‑stimulated responses generated in primary 
culture
Acute PRR-stimulated innate immune responses pro-
vide additional insight into immune capacity. Here, pri-
mary culture supernatants were generated by stimulation 
Fig. 4 Pro- and anti-inflammatory cytokines (a), acute phase proteins and inflammatory biomarkers (b) in serum, as well as plasma, remain stable 
despite repeated freeze/thaw cycles but the values obtained from the two sources are often distinct. Serum and plasma were obtained from a set 
of individuals and analysed both immediately and following five freeze/thaw cycles
Fig. 5 The stability of pro-inflammatory (a) and anti-inflammatory (b) plasma biomarkers is similar in both pediatric and adult populations. Sex 
does not alter the freeze/thaw stability of these plasma biomarkers
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of fresh PBMC with agonists for a representative TLR 
(TLR4 using LPS, n =  20 experiments, Fig.  6a) or RLR 
(RIG-I/MDA-5 using Lyovec conjugated poly:IC, n = 30 
experiments, Fig. 6b) ligand. Both pro- and anti-inflam-
matory responses were stable for at least five F/T cycles.
Discussion
Human inflammatory disease research is hampered by 
use of a relatively small number of biomarkers to trans-
late findings from basic biomedical research into large 
scale cohorts. Here we demonstrate a panel of 14 in vivo 
biomarkers of pro- and anti-inflammatory status that are 
readily quantifiable in plasma of healthy adult and pedi-
atric populations. The results also demonstrate that no 
differences are evident when comparing fresh/never fro-
zen samples with those that had undergone up to five F/T 
cycles. Similarly, a panel of biomarkers of innate PRR-
mediated activation remained stable in supernatants 
obtained after cell culture stimulation, directly ex  vivo, 
despite repeated freeze thaw cycles. Thus, extending 
findings from individual murine and human analyses 
of inflammatory disorders to large human cohorts by 
obtaining more comprehensive innate immune signa-
tures is readily feasible.
Prior literature on F/T stability has yielded contradic-
tory conclusions. A representative early study (with four 
healthy and three HIV-infected volunteers) indicated F/T 
stability for the biomarkers examined [35] as did similar 
studies [36, 37]. Others disagreed, finding substantial 
sensitivity to F/T [38–41]. Using four healthy individuals, 
De Jager et al. [27] concluded that samples for cytokine 
measurements could not be subjected to repeated F/T 
cycles because only two of the 15 cytokines they exam-
ined did not show alterations in mean levels.
Important caveats to be aware of in interpretation 
of the literature include: (1) due to limited assay sensi-
tivity, many investigators utilized samples spiked with 
recombinant cytokines to achieve sufficient sensitivity 
for the assays employed, (2) the number of individuals 
studied in most studies was often less than ten, (3) intra- 
and inter-assay variation was often not provided, mak-
ing it difficult to determine to what extent decreases or 
increases in reported cytokine levels were attributable to 
variability in assay or operator performance rather than 
F/T cycles. Moreover, in many studies, means and para-
metric statistical tests with significance set at 0.05 were 
utilized, without correction for non-parametric data dis-
tributions (log-transformation or use of non-parametric 
tests such as utilized above) common to small data sets 
or correcting for multiple comparisons (i.e. Bonferroni 
corrections).
When statistically significant differences are identified, 
it will be important to examine the scale of such differ-
ences in the context of the population being examined. 
For example, here, sTNF-RII levels were significantly 
different following one versus five F/T cycles (medians 
1516 vs. 1470  pg/mL, a 3% increase, p =  0.002). While 
variance is inherent in repeated analyses of any quanti-
tative measure, it needs to be compared in scale to the 
range exhibited within the study population as a whole. 
Thus, for sTNFRII, there is a 770% (560–4365  pg/mL) 
range in values within the population studied. Similarly, 
Fig. 6 Stability of pro- and anti-inflammatory biomarkers following acute PRR-mediated [TLR4 (a), RLR (b)] stimulation in vitro
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the ranges of CXCL10 (2500% or 25-fold range between 
weakest and strongest), IL-18 (>125 fold), TNFα (>1000 
fold) and IL-10 (>3000 fold) seen in this relatively small 
human population (n =  140) are important to weigh in 
assessing biological as well as statistical significance even 
when a small, statistically significant difference is con-
tributed by sample handling.
This study has important caveats. The focus here was 
on the capacity to reproducibly quantify pro-/anti-
inflammatory biomarker concentrations ex  vivo, despite 
virtually inevitable F/T cycles. We did not attempt to 
determine biological activity (i.e. therapeutic potential), 
nor did we assess the stability of recombinant proteins 
in these assays. Other (largely controllable) factors can 
introduce sample variability and, depending on the study 
design utilized, need to be considered individually. Simi-
larly, immune biomarkers such as Type I or III Interfer-
ons (18) that were not examined in this study may exhibit 
sensitivity to F/T cycles. As additional biomarkers are 
added, it will be important to examine each explicitly 
prior to undertaking large-scale analyses. Other control-
lable variables, including operator error, assay variance 
and so forth may also introduce variance. This underlines 
the need for well-defined standard operating procedures 
(SOPs). Finally, proving that something does not occur is 
impossible. For that reason, this study utilized well over 
100 different individuals. Variation might become detect-
able if 1000 or 100,000 individuals were examined, but 
if thousands or more samples are required to detect a 
difference, the size of that effect would by definition be 
minor.
One concern not addressed here is the long term sta-
bility of biomarkers after years of storage. Addressing 
this variable was beyond the scope of the present study. 
Use of cross-sectional study designs when compar-
ing samples in a longitudinal cohort after three, five or 
seven years of storage provide an interim workaround 
until better data on long term stability are available. 
Thus, comparison can be made of samples of the same 
age from individuals exhibiting versus not exhibiting a 
given clinical phenotype is feasible, if imperfect. Cer-
tainly, prioritizing analyses to the earliest possible time 
point is important.
Finally, while commonly known, an important practical 
aspect in the implementation of such analyses should be 
reiterated. Logistical constraints on assay manufacturers 
preclude provision of constant standards from one assay 
to another purchased a few months or years later. This 
underlines the importance of establishing substantial ali-
quots of a single internal lab standard to be used for each 
assay to allow inter-assay comparison.
Conclusions
Human cohorts generate tens of thousands of biological 
samples, often at multiple sites. It is impossible to exam-
ine samples for all analytes simultaneously. The results 
above provide the foundation (and confidence) for large 
scale analyses of panels of inflammatory biomarkers to 
better understand immunological mechanisms under-
lying health versus disease. Specifically, the data dem-
onstrate that an extensive panel of pro-inflammatory 
(CCL2, CXCL10, IL-18, TNFα, IL-6), anti-inflammatory 
(IL-10, sTNF-RII, IL-1Ra), acute phase proteins (CRP, 
PTX3) and other biomarkers (sST2, IL-1RAcP) linked to 
allergy and autoimmunity and other inflammatory dis-
eases in basic discovery research are readily detectable, 
even in healthy control individuals, and that they remain 
stable for repeat analysis despite multiple freeze thaw 
cycles. More frequent and more comprehensive examina-
tion of innate immune signatures would greatly enhance 
the value obtained from large multi-centre human cohort 
studies.
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